Christine Lasset

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

Sylvie Négrier, Bernard Escudier, Christine Lasset et al. · New England Journal of Medicine · 1998 · 969 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype

Gaël Grelier, Nicolas Voirin, A-S Ay et al. · British Journal of Cancer · 2009 · 199 citations · Full text

Medicine, Molecular Biology, Oncology +17

Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6—From the Groupe Français d'Immunothérapie

Sylvie Négrier, David Pérol, Christine Ménétrier‐Caux et al. · Journal of Clinical Oncology · 2004 · 175 citations · Full text

Medicine, Immunology, Oncology +17

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer.

Philippe Thiesse, L. Ollivier, D. Di Stefano-Louineau et al. · Journal of Clinical Oncology · 1997 · 168 citations

Medicine, Oncology, Cancer Immunology +16

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

Ruth Ladenstein, Thierry Philip, Christine Lasset et al. · Journal of Clinical Oncology · 1998 · 166 citations · Full text

Medicine, Oncology, Surgery +8